Results 121 to 130 of about 14,687 (252)

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1156-1159, May 2026.
ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or ...
Priya Jayachandran, Mayur K. Ladumor, Georgios Vlasakakis, Andrew Riselli, Katarina V. Ilic, Rob C. van Wijk, Mohamed Elmeliegy, Jatinder Kaur Mukker, Aarti Sawant‐Basak, Tao Long, Juyao Dong, Noha Rayad, Tao Zhang, on behalf of the DRO Network   +13 more
wiley   +1 more source

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1195-1204, May 2026.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, Marta Boffito, René Holm, Zack Panos, Imelda Mahaka, Francois Venter, Benny Kottiri, Keith W. Crawford, Rodney J. Y. Ho, Polly Clayden, Paul Domanico, Kimberly Struble, Andrew Owen, Charles Flexner   +22 more
wiley   +1 more source

Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach

Frontiers in Pharmacology
Purpose: This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and pulmonary EGFRm+ (T790M and L858R mutants) inhibition in Caucasian, Japanese,
Feng Liang, Yimei Zhang, Qian Xue, Na Yao   +3 more
doaj   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

How to integrate in vitro PK/PD information for toxicity prediction [PDF]

, 2009
Predicting drugs' in vivo effects from in vitro testing requires modelling processes that are not reproduced by in vitro systems. The most obvious difference between the two situations is the absence of the absorption, distribution, metabolism, and ...
Bois, Frédéric Y.
core   +1 more source

Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Impact of concomitant medications (conmeds) on the safety of the investigational agent is often evaluated using subgroup analyses for safety events in patients who received the conmed versus those who did not. Here, we highlight the potential biases and inconclusive results that can arise from such analyses, using talazoparib and P ...
Diane Wang, Charvi Nanavati, Derek Z. Yang, Liza DeAnnuntis, Mohamed Elmeliegy   +4 more
wiley   +1 more source

Contaminants of emerging concern in agricultural soils: Current understanding, overlooked issues, and future priorities

PLANTS, PEOPLE, PLANET, Volume 8, Issue 3, Page 792-810, May 2026.
Contaminants of emerging concern (CECs) in agriculture represent a growing global challenge for food safety and public health. In this review, we synthesized evidence on how substances such as pharmaceuticals, microplastics, and per‐ and polyfluoroalkyl substances (PFAS) enter soils, accumulate in crops, and affect ecological and human health. We found
Laura J. Carter, Evyatar Ben Mordechay, Benny Chefetz, Zeyou Chen, Xinyi Cui, Jay Gan, Hui Li, Audrey Moores, Xiaoyu Gao   +8 more
wiley   +1 more source

A tutorial on physiologically based pharmacokinetic approaches in lactation research

CPT: Pharmacometrics & Systems Pharmacology
In breastfeeding mothers, managing medical conditions presents unique challenges, particularly concerning medication use and breastfeeding practices.
Amita Pansari, Xian Pan, Lisa M. Almond, Karen Rowland‐Yeo   +3 more
doaj   +1 more source

Machine Learning Meets Pharmacokinetics: A Comparative Analysis of Predictive Models for Plasma Concentration‐Time Profiles

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Predicting pharmacokinetic (PK) profiles from molecular structures represents a significant advancement in pharmaceutical research with substantial implications for expediting drug discovery processes. We evaluated five approaches to systematically compare five distinct methodological frameworks for predicting rat plasma concentration‐time ...
Felix Jost, Clemens Giegerich, Christoph Grebner, Hans Matter, Henrik Cordes   +4 more
wiley   +1 more source